New biologic logic – Multispecific antibodies extend targeted therapy beyond one antigen or pathway. By combining binding sites, cell recruitment and defined valencies within one molecule, they enable mechanisms that conventional monoclonal antibodies or their combinations cannot reproduce with the same spatial and pharmacological control.
AI can already reduce administrative work, improve decision-making and streamline parts of clinical development. But its impact is often overstated. Evidenze’s Raphaela Schnurbus explains where AI is delivering measurable value today, where human expertise remains essential and what biotechs should ask before buying in.
At the IZB in Martinsried, Invitris is developing a cell-free platform to turn digital sequences into proteins, antibodies and phages within hours. CEO Patrick Grossmann explains why AI is shifting the bottleneck from drug design to manufacturing, how Phactory™ addresses phage production and why microgravity could open new possibilities.
Helping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start.
AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, Chief Development Officer, explain the development program, the choice of bronchiectasis and the upcoming Phase 1b/2a trial.
Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.
For CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales.
Justyna Adamczyk, Associate VP Integrated MS&T at Rezon Bio, discusses why integrating development and manufacturing strategies is key to improving late-stage efficiency and commercialization readiness.
Customized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global leadership.